Screener
4D Molecular Therapeutics FDMT Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $70.37M-8.8% | $72.49M-45.7% | $60.24M-59.7% | $48.56M-74.1% | $77.16M-59.2% | ||
| $290.96M+34.7% | $318.4M+69.4% | $342.41M+24.3% | $256.51M-18.4% | $216.07M-38.8% | ||
| $382.96M+26.3% | $405.36M+21.9% | $413.13M-5.0% | $312.38M-38.8% | $303.29M-45.1% | ||
| $12.38M-29.3% | $13.59M-27.5% | $14.87M-23.9% | $16.15M-18.7% | $17.51M-6.7% | ||
| $492.62M+4.0% | $512.91M-0.5% | $566.71M+1.1% | $423.98M-29.8% | $473.64M-23.6% | ||
| $12.52M+43.9% | $14.69M+254% | $11.16M+154% | $6.86M+135% | $8.7M+154% | ||
| $360K-66.2% | $360K-58.4% | $360K+40.1% | $360K+929% | $1.07M— | ||
| $47.67M+37.5% | $43.4M+61.4% | $43.99M+50.9% | $37.11M+25.9% | $34.68M+78.7% | ||
| $19.59M— | —— | $0— | —— | —— | ||
| $84.96M+61.1% | $61.07M+32.7% | $61.05M+22.6% | $55M+7.7% | $52.75M+66.0% | ||
| $6K+20.0% | $5K0.0% | $6K+20.0% | $5K0.0% | $5K0.0% | ||
| -$858M-26.4% | -$785.06M-25.8% | -$716.3M-24.3% | -$735.7M-39.7% | -$678.83M-40.6% | ||
| $407.66M-3.1% | $451.84M-3.8% | $505.66M-1.0% | $368.98M-33.3% | $420.89M-28.5% | ||
| $492.62M+4.0% | $512.91M-0.5% | $566.71M+1.1% | $423.98M-29.8% | $473.64M-23.6% |
FAQ
- What are 4D Molecular Therapeutics's total assets?
- 4D Molecular Therapeutics (FDMT) holds $492.6M in total assets, up 4.0% year over year.
- How much debt does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics carries $39.2M in total debt against $407.7M of shareholders' equity, a debt-to-equity ratio of 0.10.
- How much cash does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics holds $70.4M in cash and equivalents.
- Can 4D Molecular Therapeutics cover its short-term obligations?
- Its current ratio is 8.03 — current assets exceed current liabilities.
- Where does 4D Molecular Therapeutics's balance sheet data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
